Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2008
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 109 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Combination With Sargramostim in Adults With Metastatic Carcinoma
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG
Who cites it
109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 228 citations in OpenAlex.
- A systematic review of the efficacy of cancer vaccines in advanced breast cancer.Breast cancer (Tokyo, Japan) · 2025Pooled it
- Antigen-specific active immunotherapy for ovarian cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.Cancer immunology, immunotherapy : CII · 2023Trial
- Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.Blood · 2017Trial
- Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Trial
- Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.JAMA oncology · 2015Trial
- Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules.Human gene therapy · 2014Trial
- Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.Cancer prevention research (Philadelphia, Pa.) · 2013Trial
- A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.Expert opinion on biological therapy · 2011Trial
- Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research.The breast journal · 2025Review
- Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen.PloS one · 2025Article
- Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.Cancer biology & medicine · 2023Review
- Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A co-formulated vaccine of irradiated cancer cells and cowpea mosaic virus improves ovarian cancer rejection.Journal of materials chemistry. B · 2023Article
- The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1/Balb/c mouse model of stage four breast cancer.Frontiers in molecular biosciences · 2023Article
- Post-Translational Modifications in Tumor-Associated Antigens as a Platform for Novel Immuno-Oncology Therapies.Cancers · 2022Review
- Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors.NPJ breast cancer · 2022Review
- Advances in Diagnosis and Therapy for Bladder Cancer.Cancers · 2022Review
- MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy.Cancer cell international · 2022Review
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
purposePoxviral vectors have a proven safety record and can be used to incorporate multiple transgenes. Prior clinical trials with poxviral vaccines have shown that immunologic tolerance to self-antigens can be broken. Carcinoembryonic antigen (CEA) and MUC-1 are overexpressed in a substantial proportion of common solid carcinomas. The primary end point of this study was vaccine safety, with immunologic and clinical responses as secondary end points. EXPERIMENTAL
designWe report here a pilot study of 25 patients treated with a poxviral vaccine regimen consisting of the genes for CEA and MUC-1, along with a triad of costimulatory molecules (TRICOM; composed of B7.1, intercellular adhesion molecule 1, and lymphocyte function-associated antigen 3) engineered into vaccinia (PANVAC-V) as a prime vaccination and into fowlpox (PANVAC-F) as a booster vaccination.
resultsThe vaccine was well tolerated. Apart from injection-site reaction, no grade > or =2 toxicity was seen in more than 2% of the cycles. Immune responses to MUC-1 and/or CEA were seen following vaccination in 9 of 16 patients tested. A patient with clear cell ovarian cancer and symptomatic ascites had a durable (18-month) clinical response radiographically and biochemically, and one breast cancer patient had a confirmed decrease of >20% in the size of large liver metastasis.
conclusionsThis vaccine strategy seems to be safe, is associated with both CD8 and CD4 immune responses, and has shown evidence of clinical activity. Further trials with this agent, either alone or in combination with immunopotentiating and other therapeutic agents, are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.